Skip to content
RDL Network logo
CLL-247 Venetoclax Plus Ibrutinib As First-line Treatment in Patients With Chronic Lymphocytic Leukemia: Meta-Analysis of Randomised Controlled Trials — Lokman Hekim Tanrıverdi (2024) | RDL Network